Trinity Capital announced the commitment of $35 million in growth capital to Neuros Medical, Inc., a MedTech company focused on alleviating chronic post-amputation pain and restoring quality of life through neuromodulation technologies.

Neuros Medical's FDA-approved Altius Direct Electrical Nerve Stimulation System targets pain at its source by interrupting peripheral nerve signals responsible for phantom limb and residual limb pain. The system enables patients to activate therapy when needed, delivering targeted pain relief without relying on continuous medication. With treatment options historically limited to opioid-based therapies, Altius offers a differentiated alternative for post-amputation pain.

"Neuros Medical has reached an important inflection point as their technology moves into real-world adoption. We are proud to continue to support their team as they expand access to a differentiated therapy that addresses a significant need within the life sciences ecosystem," said Rob Lake, Senior Managing Director, Life Sciences at Trinity Capital.

This new capital will help Neuros Medical scale the commercialization of the Altius system and expand into new markets.

"We appreciate the continued partnership from Trinity," said David Veino, President & CEO of Neuros Medical. "The Trinity team has been an important partner prior to us achieving FDA approval and will remain an important partner as we expand. This expansion of our debt facility provides important financial flexibility as Neuros enters the next phase of its mission to Relieve Pain and Restore Life for this underserved patient population."